The text starts here.

News Release

FOR IMMEDIATE RELEASE
No.06-18
May 9, 2006
For Print (PDF 212KB)

Eisai will initiate first clinical study for E2012, a potential new treatment for Alzheimer's Disease


Eisai Medical Research Inc. (Headquarters: New Jersey, President: Mindell Seidlin), the U.S. clinical research subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito), announced today that it will initiate a Phase I clinical trial for E2012, a gamma secretase modulator that will be evaluated as a potential new treatment for Alzheimer's disease.

The cause of Alzheimer's disease is not fully understood, but the deposition of the beta-amyloid Abeta 40/42 and the subsequent damage to nerve cells in the brain is thought to be a cause. Beta-amyloid is produced by beta- and gamma-secretases from the amyloid precursor protein. Gamma secretase inhibitors are thought to suppress the production of beta-amyloids but also are believed to interfere with the Notch-processing that is a key process in normal cell differentiation. E2012, a new chemical entity discovered by Eisai, has shown some potential in non-clinical studies to reduce the production of beta-amyloid Abeta 40/42 by modulating the function of gamma secretase without interfering with the Notch-processing.

The need for a next generation Alzheimer's disease treatment with disease modifying potential is increasing. E2012 is one of Eisai's attempts to address the need through modifying beta-amyloid production process. It will be evaluated as a potential new type of treatment for the improvement of Alzheimer's disease condition.

As a leader in Alzheimer's disease therapy through its marketed product, Aricept(R) (donepezil hydrochloride tablets) an acetylcholinesterase inhibitor, Eisai is endeavoring to discover and develop new therapies for this disease through multi-faceted approaches, including investigation of genes responsible for the onset of the disease, immunotherapy and vaccine therapy.


Contacts:
Corporate Communications Department
Eisai Co., Ltd.
TEL: +81-3-3817-5120


[Reference]

[Characteristic Description of E2012]

Beta-amyloid Abeta 40/42, that is thought to be a cause of Alzheimer's disease, is produced by enzymatic reactions with beta- and gamma-secretases on the amyloid precursor protein (APP).   (Fig. 1)
Fig. 1


Gamma secretase inhibitors are thought to suppress the production of beta-amyloids but also are believed to interfere with the Notch-processing that is a key process in the normal cell differentiation.   (Fig. 2)
E2012, a new chemical entity discovered by Eisai, has shown some potential in non-clinical studies to reduce the production of beta-amyloid Abeta 40/42 by modulating the function of gamma secretase but without interfering with the Notch-processing.   (Fig. 3)
Fig. 2 Fig. 3